Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect Chemomab Therapeutics to post earnings of ($0.20) per share for the quarter.
Chemomab Therapeutics Price Performance
Shares of NASDAQ:CMMB opened at $1.33 on Tuesday. The business has a 50 day simple moving average of $1.24 and a two-hundred day simple moving average of $1.61. Chemomab Therapeutics has a 1 year low of $0.60 and a 1 year high of $2.55. The firm has a market capitalization of $19.10 million, a PE ratio of -1.33 and a beta of 0.55.
Analysts Set New Price Targets
Separately, Maxim Group lifted their price target on shares of Chemomab Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, February 20th.
About Chemomab Therapeutics
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
See Also
- Five stocks we like better than Chemomab Therapeutics
- The Role Economic Reports Play in a Successful Investment Strategy
- Chevron’s Fundamentals Shine Through Market Turmoil
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Qualcomm: Analyst Opinions Split, But Upside Potential Remains
- What Makes a Stock a Good Dividend Stock?
- Monster Beverage Stock: Short Report Risks vs Upside Potential
Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
